The growth of Viagra and its effect on the pharmaceutical landscape presents a intricate question for shareholders. While the early sales figures were astounding, the patent has lapsed, leading to a deluge of generic alternatives that are eroding earnings. In addition, the sector is facing issues related to demographic trends and shifting healthcar